Cloning the Promoter of the Human Adiponectin Gene and Research on its Luciferase Activity

CUI Lin; LI Qiang; LU Ling-ling; ZAI Jun-hua; ZHANG Sha-sha

您当前的位置：

首页 >

文章列表页 >

Cloning the Promoter of the Human Adiponectin Gene and Research on its Luciferase Activity

更新时间：2024-01-04

- Cloning the Promoter of the Human Adiponectin Gene and Research on its Luciferase Activity
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 19, Issue 6, Pages: 211-215(2013)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published：2013
- 稿件说明：
移动端阅览
CUI Lin, LI Qiang, LU Ling-ling, et al. Cloning the Promoter of the Human Adiponectin Gene and Research on its Luciferase Activity[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(6): 211-215.
DOI：

CUI Lin, LI Qiang, LU Ling-ling, et al. Cloning the Promoter of the Human Adiponectin Gene and Research on its Luciferase Activity[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(6): 211-215. DOI：

摘要

目的: 通过将1 100 bp长度的人脂联素(adiponectin

AD)启动子上游的调控基因(包括启动子

-1066 To+4 bp)插入荧光素酶报告基因载体pGL3-Basic中

构建成含启动子调控序列的荧光素酶报告基因(pGL3-Basic-ADI1100)

用于脂联素在中国仓鼠卵巢细胞(CHO)中的表达调控研究。方法: 利用PCR技术扩增1 100 bp长度AD启动子片段

与PUC19T载体连接

将PUC19T-ADI1100质粒

及荧光素酶报告基因pGL3-Basic质粒转染大肠肝菌(DH5a)后扩增

提取并纯化PUC19T-ADI1100和pGL3-Basic;分别以KpnI

XhoI酶切pGL3-Basic;电泳并回收ADI1100片段和pGL3-Basic酶切大片段

在T4 DNA 连接酶的作用下

将ADI1100片段插入荧光素酶报告基因pGL3-Basic中

并转染CHO细胞

检测荧光素酶报告基因活性。结果: 通过酶切及基因测序的方法证实所构建质粒含有脂联素启动子上游调控序列;瞬时转染实验显示AD启动子在CHO细胞中的转录表达随时间的变化而升高

转染后48 h的双报告基因活性是pGL3-Basic的30倍。结论: 该荧光素酶报告基因构建成功

为后续筛选有抑制肥胖作用的中药提供基础。

Abstract

Objective: To clone the promoter of the adiponectin gene and investigate its transcriptional activity in the Chinese hamster ovary cells(CHO) cell lines. Method: The promoter of the human adiponectin gene was amplified from human genomic DNA by PCR

and then it was subcloned into PUC-19T and luciferase reporter gene.The Luciferase report systems with the promoter of the adiponectin gene were used to transfer CHO cells.The luciferase activities of the transferred cells were compared by luciferase assay. Result: The luciferase activity demonstrated that the constructed vector had the promotor activity.The CHO cells presented a stronger adiponectin promoter activity in 48 h than pGL-3basic vector. Conclusion: The human adiponecitin luciferase reporter gene vector has been constructed successfully

and it will become essential material for further study of obesity therapy with the traditional Chinese medicine.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Buyang Huanwutang Alleviates Inflammatory Injury After Cerebral Ischemia-reperfusion in Rats via Activating Adiponectin Pathway

Nonalcoholic Fatty Liver Disease Effect of Emodin Based on AMPK Signaling Pathway

Effect of Diosgenin on Expressions of PPARγ, C/EBPα and Adipokine Secretion in Aplastic Anemia Mice

Effects of Total Saponins from Balsam Pear on Insulin Resistance, Adiponectin and Leptin in Rat Model of Type 2 Diabetes

Pharmacodynamic Study on Compatibility of Astragalus Active Ingredients in Diabetes Rats

Related Author

GAO Yurong

ZHANG Yaxing

WU Fanghua

DAI Jiaying

LIU Wei

Lin-yuan YU

Li-hong GONG

Yun-qiu TANG

Related Institution

School of Basic Medical Sciences， Guangzhou University of Chinese Medicine

Key Laboratory of Systematic Research, Development and Utilization of Chinese Medicine Resources in Sichuan Province, Key Laboratory Breeding Base of Co-founded by Sichuan Province and Ministry of Science and Technology, Pharmacy College, Chengdu University of Traditional Chinese Medicine

General Hospital of Tianjin Medical University

Graduate School of Tianjin University of Traditional Chinese Medicine

Endocrinological Department of the First Affiliated Hospital, Xinxiang Medical University,Weihui

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰